Patent ID: 6232333
Filing Date: 2001-05-15
Classification: A61K

Abstract:
A pharmaceutical composition for oral administration which is a solution comprising:(a) an HIV protease inhibiting compound which is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane (ritonavir),(b) a pharmaceutically acceptable organic solvent which comprises a pharmaceutically acceptable long chain fatty acid or a mixture of a pharmaceutically acceptable long chain fatty acid selected from the group consisting of saturated, mono-unsaturated and di-unsaturated C.sub.12 to C.sub.18 carboxylic acids which are liquids at room temperature and a pharmaceutically acceptable alcohol, and, optionally,(c) a pharmaceutically acceptable surfactant.